Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Conditions
Keywords
Immune microenvironment
Brief summary
This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.
Interventions
OTHERCollection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
Sponsors
Abramson Cancer Center at Penn Medicine
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Women 18 years of age or older with non-metastatic breast cancer undergoing surgical resection in the University of Pennsylvania Health System.
Exclusion criteria
Males Children Pregnant individuals
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Collecting, processing and archiving breast cancer tumor tissues | Through study completion, average of 2 years | This study will collect and analyze tumor samples from women diagnosed with primary breast cancer. The investigators will dissociate fresh tumor samples and analyze single cell suspensions by flow cytometry. Percentage of dendritic cell and T cell subsets and dendritic cell and T cell activation markers will be compared between breast cancer subtypes (HR+HER2-, HER2+, triple negative). Percentage of dendritic cell and T cell subsets and dendritic cell and T cell activation markers will be compared between HR+HER2- untreated breast cancers compared to HR+HER2- chemotherapy treated breast cancers. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Associating breast cancer dendritic cell infiltrate with outcome | 5 years | We will perform studies to associate dendritic cell infiltration and activation markers with patient outcome, including disease free survival, distant disease free survival, and overall survival. |
Countries
United States
Contacts
Primary ContactJulia T. Lewandowski
Backup ContactJennifer Zhang, MD
Outcome results
None listed